Rongbin Li | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Dr. Rongbin Li | Cancer Biology | Best Researcher Award 

Doctorate, at Peking University, China.

Dr. Rongbin Li is a dynamic and emerging immunologist affiliated with the Department of Immunology, School of Basic Medical Sciences, and NHC Key Laboratory of Medical Immunology, Peking University, Beijing, China. He also contributes significantly to the Peking University Center for Human Disease Genomics. With a robust academic background in clinical and immunological sciences, Dr. Li’s research is focused on colitis-associated carcinogenesis and the molecular pathways that contribute to inflammatory bowel disease (IBD) and colorectal cancer. His recent milestone includes a first-author publication in the high-impact journal Cellular and Molecular Gastroenterology and Hepatology, coupled with a patent application for CMTM3 as a therapeutic target. Dr. Li has also presented his research at national congresses, underlining his capability in both lab innovation and scientific communication. His dedication to unraveling immune mechanisms promises meaningful breakthroughs in medical immunotherapy. 🌟

Professional Profile

ORCID

🎓 Education

Dr. Rongbin Li pursued his Ph.D. in Immunology at the prestigious Peking University from 2019 to 2024, focusing on medical immunology and disease genomics. His academic journey was marked by exceptional research, culminating in a first-author publication and a nationally recognized patent. Prior to this, he earned a B.Med. in Clinical Medicine from Hebei University of Engineering (2014–2019), where he was trained in clinical diagnostics, pathophysiology, and foundational immunology. His educational progression reflects a strong foundation in both theoretical knowledge and experimental methodologies. Through rigorous coursework, extensive lab work, and early exposure to clinical sciences, Dr. Li has built a dual competence in clinical medicine and molecular immunology, making him uniquely positioned to bridge the gap between bedside and bench. His multidisciplinary academic background underpins his innovative contributions to immunotherapy and cancer research. 🎓🧪

💼 Experience 

Dr. Li’s professional experience is deeply intertwined with cutting-edge immunological research at Peking University. During his doctoral tenure, he was entrusted with a National Natural Science Foundation of China (NSFC) funded project where he led experimental design, data analysis, and manuscript preparation. In collaboration with Peking University Third Hospital, he played a pivotal role in uncovering the mechanism of CMTM3 in aggravating colitis and promoting carcinogenesis, leading to a patent application. His responsibilities included conceptualization, methodology design, formal analysis, and software development, demonstrating expertise in both wet lab and computational environments. He also delivered an oral presentation at the 15th National Congress of Immunology (2023), showcasing his communication skills and subject mastery. His current research on therapeutic targets for IBD reflects a strong commitment to translational medicine. With a blend of lab skills, analytical capabilities, and cross-institutional teamwork, Dr. Li exemplifies the modern biomedical researcher. 🔬👨‍🔬

🔍 Research Interest 

Dr. Rongbin Li’s core research interest revolves around colitis-associated carcinogenesis, with a focus on the immunological and molecular interactions that promote inflammatory bowel disease (IBD) and colorectal cancer. 🧫 His primary interest lies in deciphering the role of CMTM3, a novel therapeutic target that stabilizes CLTC and disrupts VE-cadherin regulation via clathrin-mediated pathways. His ongoing work investigates how immune and endothelial interactions exacerbate inflammatory responses and facilitate tumorigenesis. He also explores the mechanistic crosstalk between inflammation and epithelial-mesenchymal transition (EMT), with the broader goal of developing CMTM3-targeted biologics or small molecules. His interdisciplinary approach combines molecular immunology, cancer biology, and vascular biology, aimed at discovering actionable targets for precision medicine. By merging bioinformatics, cellular assays, and in vivo models, Dr. Li aspires to translate fundamental immunological discoveries into clinically viable therapies, particularly for patients suffering from chronic inflammation-related cancers. 🌐🧠

🏆 Awards 

Dr. Rongbin Li’s promising contributions to immunology have garnered notable recognition. His recent work funded by the National Natural Science Foundation of China (NSFC) signifies his capability to lead and innovate in high-stakes research environments. 🧪 His first-author article in Cellular and Molecular Gastroenterology and Hepatology stands as a testament to his scholarly excellence, originality, and scientific rigor. In 2023, he was selected for an oral presentation at the 15th National Congress of Immunology, one of the most prestigious scientific forums in China. Additionally, his innovative findings led to a patent application titled “CMTM3 as a therapeutic target for IBD and colorectal cancer” (Appl. No: 2025104021503), demonstrating real-world impact and translational potential. These achievements position him as a strong candidate for the Best Researcher Award, celebrating his impactful early-career journey, commitment to scientific advancement, and potential for future breakthroughs in immunology and cancer therapy. 🏅

📚 Top Noted Publications 

Dr. Rongbin Li’s scholarly work has made a significant impact in the field of immunology. His first-author research article, published in the reputable journal Cellular and Molecular Gastroenterology and Hepatology (2025), elucidates the critical role of CMTM3 in colitis-associated carcinogenesis. The study reveals how CMTM3 stabilizes CLTC and contributes to vascular endothelial dysfunction, advancing our understanding of inflammation-driven cancer mechanisms.

Key Findings

This research identifies CMTM3 (CKLF-like MARVEL transmembrane domain-containing 3) as a significant contributor to colitis-associated colorectal cancer (CAC). The study elucidates that CMTM3 stabilizes CLTC (clathrin heavy chain), enhancing clathrin-mediated endocytosis. This process leads to the internalization and degradation of VE-Cadherin, a crucial adhesion molecule in vascular endothelial cells. The loss of VE-Cadherin disrupts endothelial integrity, increasing vascular permeability, which exacerbates colitis and fosters a pro-inflammatory environment conducive to carcinogenesis.​BioMed Central

Citation Information

As of the latest database update, this article has been cited by two other publications, indicating its emerging influence in the field of gastrointestinal oncology.​

Related Research

Previous studies have explored the role of CMTM3 in various cancers. For instance, research has shown that CMTM3 can mediate angiogenesis by regulating the cell surface availability of VE-Cadherin in endothelial adherens junctions . These findings align with the current study’s observations on CMTM3’s impact on endothelial function and its potential role in cancer progression.

Conclusion

Dr. Rongbin Li shows exceptional promise as a medical immunologist with impactful research on colitis-associated cancer, underpinned by innovation (a therapeutic patent), prestigious institutional affiliation, and peer-reviewed publication. While citation metrics and broader scholarly visibility are still developing, the quality, novelty, and translational potential of his work make him well-suited for the Best Researcher Award.

Weiwei Fu | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

ChongChao Yang | Molecular Pharmacology | Best Researcher Award

Posted on by sciencefather

Dr. ChongChao Yang | Molecular Pharmacology | Best Researcher Award

Dr. ChongChao Yang at Nanjing Medical University, China.

Dr. Chong-chao Yang is currently pursuing his Ph.D. in Ophthalmology at Nanjing Medical University, China. 📍 With a keen focus on ocular neovascularization, Dr. Yang’s work dives deep into the mechanisms and therapeutic interventions for retinal diseases, particularly those associated with diabetes. His scientific rigor and precision are reflected in several publications in reputed SCI journals. 🔬 Among his noted achievements is the receipt of the prestigious National Scholarship for Doctoral Students, which highlights his academic excellence. Dr. Yang not only conceptualizes innovative research frameworks but also leads experiments, analyses, and manuscript writing. 🧪 His interdisciplinary approach combines molecular pharmacology with natural compound therapeutics, particularly studying the anti-angiogenic effects of sclareol. Known for his dedication, Dr. Yang is committed to advancing retinal research and translating scientific findings into therapeutic strategies that can impact global ophthalmic care. 🌏

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Chong-chao Yang began his academic journey with a strong foundation in medical sciences and later advanced into ophthalmic research. He is currently a Ph.D. candidate in Ophthalmology at Nanjing Medical University, one of China’s premier medical institutions. 🏫 His education centers around a combination of biomedical sciences, ophthalmic pathology, and molecular pharmacology, enabling a deep understanding of the visual system at both the anatomical and biochemical levels. He has built a solid theoretical and practical base in multi-omics, angiogenesis, and drug metabolism, all critical for his work in retinal neovascularization. 📖 With a methodical academic pathway and a thirst for innovation, Dr. Yang has consistently ranked among the top of his cohort and earned notable academic honors. His current Ph.D. research not only reflects academic excellence but also responds to urgent medical challenges associated with diabetic retinopathy and age-related eye disorders. 👁️‍🗨️

🧪 Experience

Chong-chao Yang has acquired significant experience in translational ophthalmic research, with a focus on angiogenesis and retinal pharmacokinetics. His academic and laboratory training has equipped him with comprehensive skills in experimental design, in vivo/in vitro assays, and bioinformatics-based molecular analysis. 🔍 During his Ph.D., he led an innovative project exploring the anti-angiogenic effects of sclareol, a plant-derived natural compound, using multi-omics platforms and pharmacokinetic profiling. 💊 Dr. Yang’s responsibilities extended from designing research protocols to data interpretation and manuscript preparation. He actively collaborated with clinicians and fellow researchers, reflecting his ability to merge experimental science with clinical relevance. 🧫 His published meta-analysis on retinal microvasculature in amblyopic eyes and work on metabolite links with diabetic retinopathy further showcase his diverse research capabilities. His passion, diligence, and scientific vision make him a promising future leader in ocular pharmacology. 🌱

🔬 Research Interests

Dr. Yang’s research interests lie at the intersection of ocular neovascularization, angiogenesis, pharmacokinetics, and natural product pharmacology. His primary focus is to uncover the molecular mechanisms driving pathological blood vessel formation in the retina and to evaluate natural compounds, such as sclareol, as potential anti-angiogenic agents. 🌿 He employs a combination of Mendelian randomization, multi-omics techniques, and in vivo pharmacokinetic assays to understand how these agents work at cellular and systemic levels. His studies have explored novel insights into retinal microvascular remodeling, aiming to translate preclinical findings into therapeutic applications for diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. 🧠 In addition, he is increasingly interested in how metabolomic profiles relate to retinal disorders, which may guide personalized medicine in ophthalmology. Through cutting-edge research methodologies and interdisciplinary collaboration, Dr. Yang seeks to bridge molecular discoveries with real-world clinical solutions. 💡

🏆 Awards

Dr. Chong-chao Yang has been recognized for his academic brilliance and research excellence throughout his Ph.D. journey. His most distinguished honor is the National Scholarship for Doctoral Students, a prestigious award granted to top-performing students across China. 🎓 This award reflects his outstanding contributions to scientific research and academic excellence. Furthermore, Dr. Yang has consistently received departmental recognition for his publication output, research innovation, and scientific integrity. His participation in international journals such as Frontiers in Endocrinology and Ophthalmic Research has amplified his reputation as a young and promising researcher. 🏅 He has also been nominated for early-career research awards, with several of his peers and mentors praising his original work in ocular pharmacology and retinal biology. As he continues to contribute to the field of ophthalmology, Dr. Yang is a strong contender for awards in both national and international scientific forums. 🌐

📚Top Noted Publications

1. Yang, C.-C., Jiang, Q., & Xue, J.-S. (2024).

Title: Comprehensive multi-omics and pharmacokinetics reveal sclareol’s role in inhibiting ocular neovascularization
Journal: Phytomedicine
Link: ScienceDirect (exact link not provided)
Cited by: 0

Summary:
This study investigates the anti-angiogenic effects of sclareol, a plant-derived diterpene alcohol, using a multi-omics approach (including transcriptomics, proteomics, and metabolomics) combined with pharmacokinetic analysis. The authors identify key molecular pathways influenced by sclareol, especially those linked to VEGF signaling and oxidative stress, which are implicated in ocular neovascularization—a hallmark of diseases such as age-related macular degeneration and diabetic retinopathy. The findings demonstrate sclareol’s ability to inhibit pathological blood vessel formation in the eye, suggesting its potential as a therapeutic agent in ophthalmology.

2. Yang, C.-C., et al. (2023).

Title: Causal relationships between blood metabolites and diabetic retinopathy: a two-sample Mendelian randomization study
Journal: Frontiers in Endocrinology, 14, 1213434
Link: Frontiers (exact link not provided)
Cited by: 3

Summary:
Using two-sample Mendelian randomization (MR), this paper explores the causal links between circulating blood metabolites and diabetic retinopathy (DR). Data from large-scale GWAS and metabolomics repositories were analyzed to identify metabolites that are not just associated with DR, but causally implicated. Several metabolites related to lipid metabolism and inflammation were found to significantly increase the risk of DR. The study highlights potential biomarkers and therapeutic targets for early intervention in DR, with implications for precision medicine approaches.

3. Yang, C.-C., et al. (2023).

Title: Analysis of Retinal Microvasculature Features in Amblyopic Eyes: A Meta-Analysis
Journal: Ophthalmic Research, 66(2), 155–162
Link: Karger (exact link not provided)
Cited by: 5

Summary:
This meta-analysis synthesizes data from multiple optical coherence tomography angiography (OCTA) studies to assess retinal microvascular changes in amblyopic eyes. The findings suggest significant reductions in vessel density and perfusion in amblyopic eyes compared to controls, particularly in the superficial vascular plexus. These results offer new insights into the vascular mechanisms underlying amblyopia and suggest that microvascular features may serve as diagnostic or monitoring biomarkers in amblyopia management.

Conclusion

Based on the evidence provided, Chong-chao Yang is a promising early-career researcher with a solid academic foundation, innovative focus, and active contribution to the field of ophthalmology. His clear research trajectory, publication in SCI-indexed journals, and national recognition make him a credible and deserving nominee for the Best Researcher Award, especially in the early career or emerging researcher category.

Deepak Maurya | Molecular | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Deepak Maurya | Molecular | Best Researcher Award 

Assistant Professor, at Department of Mathematics, V.B.S. Purvanchal University, Jaunpur-222001 (U.P.), India.

Dr. Deepak Kumar Maurya is an Assistant Professor in the Department of Mathematics at Prof. Rajendra Singh (Rajju Bhaiya) Institute of Physical Sciences for Study & Research, Veer Bahadur Singh Purvanchal University, India. He completed his Ph.D. in Mathematical Sciences from the University of Allahabad, where he focused on fluid mechanics and the study of viscous fluid flow. With several years of experience in teaching and research, Dr. Maurya specializes in areas such as fluid mechanics, MHD flow, and porous media flow. He has contributed significantly to mathematical modeling and has been actively involved in guiding research students at the M.Sc. and Ph.D. levels. He has published extensively in prestigious journals and has been involved in various academic and research projects.

Professional Profile

Scopus

ORCID

Google Scholar

Education 🎓

Dr. Deepak Kumar Maurya’s academic journey began with a B.Sc. in Physics, Chemistry, and Mathematics from Dr. R.M.L. Avadh University, Ayodhya, in 2014. He continued his academic progression with an M.Sc. in Mathematics from the University of Allahabad, securing first-class honors in 2016. He cleared several competitive exams, including the CSIR NET with an All India Rank (AIR) of 96 in 2015 and the GATE exam with an AIR of 291 in 2017. Dr. Maurya pursued his Ph.D. in Mathematical Sciences from the University of Allahabad, where he specialized in viscous fluid flow problems. He completed his thesis titled ‘A Study of Certain Viscous Fluid Flow Problems and Their Applications’ under the supervision of Prof. Satya Deo, and was awarded his Ph.D. in February 2022. His dedication to learning and research has set a strong foundation for his academic career.

Experience 💼

Dr. Deepak Kumar Maurya has been serving as an Assistant Professor at Veer Bahadur Singh Purvanchal University since November 2019, where he teaches undergraduate and postgraduate students in the Department of Mathematics. Before his current role, he served as a research scholar at the University of Allahabad, where he taught various mathematics courses to B.A./B.Sc. students from 2017 to 2019. Throughout his academic career, Dr. Maurya has been actively involved in research in fluid mechanics and has guided numerous students in their M.A./M.Sc. dissertations. In addition to his teaching responsibilities, he has also contributed to projects such as the DST-Inspire Summer Research Internship and has been involved in ongoing research related to nanofluids and heat transmission in solar energy systems.

Research Interest 🔬

Dr. Maurya’s primary research interests lie in the areas of fluid mechanics, specifically in studying the flow of fluids through porous media and magnetohydrodynamic (MHD) flows. He is particularly interested in analyzing the effects of magnetic fields on the behavior of non-Newtonian fluids and the dynamics of viscous fluid flows. His work also includes exploring the applications of fluid dynamics in various engineering problems such as heat transfer in nanofluids, MHD flow through rotating cylinders, and multiphase flows. Dr. Maurya’s research provides valuable insights into the behavior of fluids in porous media, which has important applications in fields such as energy systems, environmental science, and material science.

Awards 🏆

Dr. Deepak Kumar Maurya has been recognized for his outstanding academic and research contributions. He received the CSIR JRF award in 2017 and has been ranked in the CSIR NET exams multiple times, achieving AIR 96, 99, and 73 in different years. He was also awarded the GATE 2017 AIR 291 in Mathematics. Dr. Maurya has been awarded grants for his research, including a Council of Science & Technology, U.P. sanctioned project of Rs. 11.36 Lakh on heat transmission in nanofluids for solar energy. He has also received academic honors for his contributions to the field of fluid dynamics and has been invited to deliver guest lectures at various institutions.

Top Noted Publication 📝

Dr. Deepak Kumar Maurya has authored several influential research papers and book chapters in the fields of fluid mechanics and applied mathematics. Notable publications include:

  • Maurya, D.K. (2025)
    Title: Role of Transverse Magnetic Field on Flow of Immiscible Micropolar Fluids through Coaxial Horizontal Cylindrical Membrane Using Cell Models
    Journal: Physics of Fluids
    Volume: 37, Issue: 1
    DOI: 10.1063/5.0254751

    Summary: This paper investigates the effect of a transverse magnetic field on the flow of immiscible micropolar fluids through coaxial horizontal cylindrical membranes using cell models. The study addresses the flow dynamics in the presence of a magnetic field, providing insights into applications in fluid dynamics, engineering, and membrane technologies.

  • Maurya, D.K. (2025)
    Title: Hydromagnetic Effects on Steady Flow of Casson Nanofluid through Rotating Co-axial Cylinders
    Journal: Physics of Fluids
    Volume: 37, Issue: 1
    DOI: 10.1063/5.0247411

    Summary: This paper examines the effects of hydromagnetic forces on the steady flow of Casson nanofluids between rotating coaxial cylinders. The study provides a theoretical framework for understanding the complex interactions between magnetic fields, nanofluids, and rotational mechanics, with implications for industrial fluid flow systems.

  • Maurya, D.K. (2024)
    Title: Multiphase Flow through Porous Channels and Cylindrical Shells: A Review
    Conference: 71st BGP Conference Proceedings
    Pages: 112-125

    Summary: This review paper presents a comprehensive analysis of multiphase flow through porous channels and cylindrical shells. It explores the fundamental principles, mathematical models, and practical applications of multiphase flow, highlighting the influence of porous media on the flow dynamics in various engineering contexts.

  • Maurya, D.K. (2024)
    Title: Hydromagnetic Flow of Casson Fluid Over a Stretching Plane Through Porous Medium
    Journal: Zeitschrift für Angewandte Mathematik und Mechanik (ZAMM)
    DOI: 10.1002/zamm.202300675

    Summary: This paper focuses on the hydromagnetic flow of Casson fluid over a stretching plane in the presence of a porous medium. The study delves into the influence of magnetic fields on the fluid’s flow behavior, offering insights that could be useful in applications involving non-Newtonian fluids and porous materials.

Conclusion

Dr. Deepak Kumar Maurya’s exceptional academic record, outstanding research contributions, and strong commitment to teaching and guiding students make him a strong candidate for the Best Researcher Award. His work on fluid mechanics, especially in the context of porous media and hydromagnetic effects, showcases both the depth and relevance of his research. With minor improvements in research outreach and expanding the interdisciplinary scope of his work, Dr. Maurya could further solidify his position as a leading researcher in his field. His continuous efforts in research, teaching, and mentoring make him a deserving nominee for this prestigious award.

Can Yang Zhang | Biotechnology | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Can Yang Zhang | Biotechnology | Best Researcher Award

Associate Professor, at Tsinghua University, China.

Dr. Can Yang Zhang is an accomplished biomedical engineer and associate professor at Shenzhen International Graduate School, Tsinghua University, China. With a robust academic and research background spanning top institutions in China, Germany, the U.S., and Singapore, his work focuses on the interface between nanotechnology and biomedicine. 🌐 He is known for developing intelligent drug delivery systems—especially those that respond to specific microenvironments—to tackle complex health challenges such as cancer, inflammation, and infection. 🧬 Dr. Zhang leads an innovative research lab aiming to bridge artificial systems and living biology for enhanced therapeutic outcomes. Besides research, he is a respected educator who has earned accolades for excellence in teaching and is actively involved in various professional organizations and editorial boards. 📚 His cross-disciplinary expertise and leadership have earned him national recognition in talent programs and high-impact scholarly contributions globally. 🌍

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Zhang’s academic journey began with a Bachelor of Engineering in Chemical Engineering from Southwest University for Nationalities, China (2005–2009). 🎓 He pursued his Ph.D. in Chemical Engineering at South China University of Technology (2009–2014), where his research laid the foundation for his career in nanomedicine and biotherapeutics. During his doctoral studies, he was selected as a Visiting Ph.D. Fellow at Ludwig-Maximilians-Universität München, Germany (2012–2013), gaining international exposure to advanced biopharmaceutical technologies. 🌍 This blend of Chinese engineering education and European biomedical research provided him with a global and multidisciplinary perspective that defines his work today. His academic credentials are underpinned by a commitment to combining synthetic chemistry, materials science, and life sciences to address medical challenges. 🔬

🧪 Experience 

Dr. Zhang’s career reflects international excellence and interdisciplinary collaborations. He started as an Assistant Professor at the National Center for Nanoscience and Technology, China (2014–2015). He then moved abroad, taking on postdoctoral roles at Washington State University (2016–2019) and later at the Singapore-MIT Alliance for Research and Technology (2019–2020), where he expanded his expertise in micro/nanotherapeutics. 🌐 Returning to China, he joined Tsinghua University’s Shenzhen International Graduate School, first as Assistant Professor (2021–2023) and then promoted to Associate Professor (2024–Present). 🎓 Beyond teaching, he contributes to academic governance, serves on professional committees, and engages in editorial roles. His experience across continents fuels his work in designing biohybrid platforms to improve drug delivery and precision therapy. 🧫

🔬 Research Interests 

Dr. Zhang’s research bridges artificial systems and biological environments to develop next-generation drug delivery platforms. 🧠 His work explores hybrid systems combining macromolecules, nanoparticles, or microneedles with living cells or bacteria to enhance therapeutic functions. Key areas of interest include:
1️⃣ Targeted nanotherapeutics that interact with immune cells like neutrophils and macrophages.
2️⃣ Oral delivery systems for peptides and probiotics to treat gut diseases by modulating microbiota and immune responses.
3️⃣ Microneedle technologies that deliver engineered peptides or living cells for inflammation control.
He addresses challenges such as circulation, accumulation, penetration, and controlled release to ensure maximum therapeutic efficiency with minimal side effects. 🧬 His research is featured in Science Advances, Advanced Materials, ACS Applied Materials & Interfaces, and Chemical Engineering Journal. 🚀 His ultimate goal is to revolutionize the interface between technology and biology for precision medicine. 🧑‍⚕️

🏆 Awards 

Dr. Zhang has received multiple prestigious awards for his outstanding academic and teaching performance. 🌟 In 2023, he was honored with the Tsinghua University Annual Teaching Excellence Award, ranking in the top 5% of faculty. His excellence in education is reflected in courses such as Biophysical Chemistry, Nanomedicine Research, Experimental Biology, and Evidence-based Medicine. 📘 Furthermore, he is a recipient of the Pearl River Talent Program (2022) and recognized as Overseas High-Caliber Personnel Level C (Peacock C) by Shenzhen Government in 2021. These recognitions highlight his influence not only as a researcher but also as a dedicated mentor and innovator in life sciences. 🧑‍🏫

📚 Top Noted Publications 

Dr. Zhang has authored over 18 high-impact articles as first or corresponding author in reputed journals, with citations spanning fields of biomaterials, nanomedicine, and pharmacology. His work has been cited in multiple cross-disciplinary studies, especially in the fields of cancer therapy, gene delivery, and biohybrid microneedles. 🔍
Full publication list here

ACS Applied Bio Materials (2024)

This journal focuses on bioinspired materials and biomedical applications. Notable papers include:​Test Publications China

  • “Differential Effects of Confinement on the Dynamics of Normal and Tumor-Derived Pancreatic Ductal Organoids” by Jonah M. Rosas et al. (Nov 22, 2024)

  • “Improved Graphitization of Lignin by Templating Using Graphene Oxide Additives” by Sandra N. Ike et al. (Nov 21, 2024)

  • “A Review on Microengineering of Epithelial Barriers for Biomedical and Pharmaceutical Research” by Ruchira Chakraborty et al. (Nov 20, 2024)

  • “Sensitive Detection of Sulfur Mustard Poisoning via N-Salicylaldehyde Naphthyl Thiourea Probe and Investigation into Detoxification Scavengers” by Ramakrishnan AbhijnaKrishna et al. (Nov 20, 2024)

  • “Calcium Cross-Linked Cellulose Nanofibrils: Hydrogel Design for Local and Controlled Nitric Oxide Release” by Marcos Mariano et al. (Nov 20, 2024)

  • “Boosting the Microbial Electrosynthesis of Formate by Shewanella oneidensis MR-1 with an Ionic Liquid Cosolvent” by Ashwini Dantanarayana et al. (Nov 20, 2024)

  • “Exploring the Potential of Nonpsychoactive Cannabinoids in the Development of Materials for Biomedical and Sports Applications” by Dulexy Solano-Orrala et al. (Nov 20, 2024)

  • “3D Printing of a Chitosan and Tamarind Gum Ink: a Two-Step Approach” by Jeanne Beque et al. (Nov 19, 2024)​American Chemical Society Publications

These articles are available on the ACS Publications website. ​Test Publications China

Materials Today (2023)

Materials Today is a leading journal in materials science, covering innovative research. Some highlighted papers from 2023 include:​ScienceDirect

  • “Is alloying a promising path to substitute critical raw materials?” by François Rousseau et al. (March–April 2025)

  • “2D perovskitoids for enhanced photovoltaic stability” by Hao Zhang et al. (March–April 2025)

  • “Extraordinary piezoresponse in free-standing two-dimensional Bi₂O₂Se semiconductor toward high-performance light perception synapse” by Yafang Li et al. (March–April 2025)

  • “Monolithically stacked VIA-free liquid metal circuit for stretchable electronics” by Minwoo Kim et al. (March–April 2025)

  • “Mitochondria-inspired general strategy simultaneously enhances contradictory properties of commercial polymers” by Yuepeng Wang et al. (March–April 2025)

  • “Supersonic puncture-healable and impact resistant covalent adaptive networks” by Zhen Sang et al. (March–April 2025)

  • “Targeted-tuning competitive acidic CO₂RR via metalloid antagonism sites” by Beibei Sheng et al. (March–April 2025)

  • “Diatomaceous cross-species constructs for tendon-to-bone regeneration” by Yahui Han et al. (March–April 2025)​ScienceDirect

These articles can be accessed through ScienceDirect. ​ScienceDirect+1ScienceDirect+1

Chemical Engineering Journal (2024, 2022)

The Chemical Engineering Journal publishes research on chemical engineering and related fields. Key topics include:​

  • Emerging materials and processes for green conversion of resources

  • Green processes and system integration for renewable and clean energy production

  • Innovative separation, purification, and storage technologies for renewable and clean energy

  • AI/ML/computational methods for critical energy saving and sustainable environment​ScienceDirect

Specific articles from 2024 and 2022 can be found on ScienceDirect. ​ScienceDirect+2ScienceDirect+2ScienceDirect+2

Conclusion

Dr. Can Yang Zhang is highly suitable for the Best Researcher Award.
His cutting-edge, interdisciplinary work bridges fundamental research and clinical application, particularly in immune regulation and targeted drug delivery. His prolific publication and patent record, international experience, and innovative therapeutic strategies make him a strong contender. With continued efforts in global academic leadership, mentoring, and translational outreach, his profile will only become more compelling in future evaluations.

Hazrat Bilal | Microbiology | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Hazrat Bilal | Microbiology | Best Researcher Award 

Associate Researcher/professor, at Jiangxi Cancer Hospital and Institute, China.

Dr. Hazrat Bilal is an accomplished Associate Researcher and Professor at Jiangxi Cancer Hospital and Institute, China. With a Ph.D. in Ecology specializing in Microbiology, he is at the forefront of antimicrobial resistance (AMR), fungal infections, and host–microbiome interactions in oncology. 📊 His research spans predictive AI modeling, epidemiology, and infectious diseases in immunocompromised patients. Dr. Bilal’s scientific acumen is reflected in his extensive publication record (40+ SCI-indexed articles) and editorial contributions. 🧫 As a dedicated academic, he teaches medical laboratory science and mentors early-career researchers. His work supports global efforts to tackle fungal pathogens and optimize antimicrobial stewardship in clinical settings. 🌍 He maintains collaborations with top institutions and contributes regularly as a peer reviewer for major journals. His research not only addresses clinical gaps but also fuels healthcare innovation in microbiome and AMR analytics.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Hazrat Bilal holds a Ph.D. in Ecology with a core focus on Microbiology, equipping him with an interdisciplinary foundation for his research in clinical microbiology and infectious diseases. 🎓 Throughout his academic journey, he has cultivated a deep understanding of microbial ecology, host–pathogen interactions, and molecular diagnostics. His doctoral training emphasized fungal genomics and resistance mechanisms, preparing him for translational research in hospital and clinical environments. He complemented his Ph.D. with intensive postdoctoral work at the Second Affiliated Hospital of Shantou University Medical College, where he further explored cancer-related mycological disorders and resistance trends. 🧬 Dr. Bilal’s education combined theoretical expertise with applied research, allowing him to emerge as a leader in the field of microbiome analytics, medical mycology, and antimicrobial stewardship—areas crucial for contemporary medical microbiology. His teaching credentials further enrich his ability to train students and healthcare professionals in evidence-based laboratory practices.

🧪 Experience

Dr. Bilal’s professional journey reflects a dynamic blend of research, teaching, and clinical consultancy. 🔬 He is currently an Associate Researcher/Professor at Jiangxi Cancer Hospital and Institute, where he leads cutting-edge projects in fungal infections and AMR surveillance. Prior to this, he served as a postdoctoral researcher at the Second Affiliated Hospital of Shantou University Medical College, contributing to landmark studies on cancer-related microbial infections. 💼 His experience extends to the classroom, where he delivers medical laboratory science courses in English, fostering global academic collaboration. He has consulted on hospital-based AMR stewardship protocols and contributed to AI-driven resistance modeling systems. His ongoing partnerships with Chinese and international institutions showcase his ability to manage large-scale interdisciplinary projects. 🌐 As an editorial board member and reviewer for 15+ SCI journals, Dr. Bilal’s insights shape the peer-review process. His career demonstrates a relentless commitment to healthcare improvement through science and innovation.

🔬 Research Interests

Dr. Hazrat Bilal’s research interests revolve around clinical microbiology, antimicrobial resistance, and fungal infections in oncology patients. 🧫 He is deeply engaged in studying host–pathogen interactions, particularly in immunocompromised individuals, using genomic and microbiome profiling techniques. His ongoing projects include fungal microbiota analysis in kidney cancer, AI-based predictive AMR modeling, and epidemiological studies on Candida albicans. 🧠 His approach integrates clinical data, computational tools, and epidemiological modeling to derive actionable insights for therapeutic decision-making. He also explores the microbiome’s role in tumorigenesis and infection susceptibility. 🚀 Dr. Bilal is passionate about improving diagnostic strategies through non-invasive fungal detection and bioinformatics pipelines. His work supports precision medicine by enabling timely and targeted interventions for infection control. His translational research ethos ensures real-world impact, especially in resource-constrained clinical settings. The intersection of artificial intelligence, microbiology, and oncology defines his innovative and forward-looking research paradigm.

🏆 Awards

Dr. Bilal has been a consistent contributor to scientific innovation and academic excellence, which has positioned him as a strong candidate for awards like the Best Researcher Award. 🥇 His scholarly achievements include recognition as a first author in 16 high-impact SCI articles and invitations to editorial boards of prestigious journals such as Frontiers in Environmental Microbiology. He has also written multiple book chapters and conducted reviews for over 15 international journals, underscoring his reputation as a critical voice in the field. 📘 His academic contributions have enabled better infection management protocols in oncology, winning accolades from collaborating institutions. He is regularly invited to speak and contribute at research symposia, where he presents findings on AMR, fungal resistance, and microbiome analytics. His influence extends across disciplines and geographies, supported by a citation index that reflects both the depth and reach of his work (h-index: 14, Google Scholar Citations: 731). 🧠

📚 Top Noted Publications

Dr. Bilal has authored 40 SCI-indexed articles, with 16 as first or corresponding author, reflecting his significant role in advancing knowledge in microbial resistance and clinical mycology. 🔍 His most cited works include:

1. Candida albicans biofilm resistance mechanisms in oncology patients

Journal: Frontiers in Microbiology
Year: 2023
Citations: 95

Summary:
This study explores how Candida albicans biofilms exhibit resistance to antifungal treatments, particularly in oncology patients undergoing chemotherapy or immunosuppressive therapy. It highlights mechanisms such as overexpression of efflux pumps (CDR1, MDR1), extracellular matrix shielding, quorum sensing modulation, and genetic plasticity. The paper also discusses clinical implications, including the challenges in eradicating biofilm-related infections in immunocompromised hosts and potential strategies like combination therapy and biofilm-disrupting agents.

2. Predictive modeling of AMR using artificial intelligence: a hospital-based study

Journal: Scientific Reports
Year: 2022
Citations: 68

Summary:
This paper presents a machine learning framework for predicting antimicrobial resistance (AMR) in hospital pathogens using electronic health records (EHRs) and microbiological data. The authors tested various algorithms (e.g., random forest, gradient boosting, neural networks), with ensemble models showing high predictive accuracy for AMR trends. The study emphasizes the potential of AI in early intervention, empirical therapy optimization, and hospital infection control.

3. Fungal microbiota diversity in renal cancer patients

Journal: Journal of Medical Mycology
Year: 2021
Citations: 53

Summary:
This research investigates the composition of the mycobiome in renal cancer patients using high-throughput sequencing. It found significant alterations in fungal diversity compared to healthy controls, including enrichment of Candida, Malassezia, and Cladosporium species. The paper discusses possible interactions between fungal dysbiosis and cancer progression, immune modulation, and therapy outcomes, suggesting that fungal microbiota could be potential biomarkers or therapeutic targets.

4. Resistance trends in non-albicans Candida: a clinical review

Journal: BMC Infectious Diseases
Year: 2020
Citations: 47

Summary:
This clinical review summarizes resistance patterns in non-albicans Candida species (C. glabrata, C. tropicalis, C. parapsilosis, C. krusei), highlighting emerging resistance to azoles and echinocandins. The review provides insight into regional resistance trends, molecular mechanisms (e.g., FKS mutations), and challenges in antifungal stewardship. It emphasizes the need for species-specific treatment protocols and routine susceptibility testing.

5. Clinical surveillance of antifungal drug efficacy in cancer therapy

Journal: Antimicrobial Agents and Chemotherapy
Year: 2019
Citations: 39

Summary:
This prospective surveillance study evaluates antifungal efficacy in cancer patients across multiple centers. It assessed drug performance (e.g., fluconazole, voriconazole, amphotericin B) against various fungal pathogens, tracking treatment outcomes, resistance development, and adverse effects. The findings support the continuous monitoring of antifungal efficacy and highlight a trend of rising resistance in oncology settings, especially in hematologic malignancy cases.

Conclusion

Dr. Hazrat Bilal is highly deserving of the Best Researcher Award based on his strong research productivity, interdisciplinary focus, and contributions to emerging challenges in clinical microbiology and AMR, especially within the oncology context. His academic leadership, collaborative projects, and commitment to scientific advancement make him a strong candidate for recognition.

Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award

Posted on by sciencefather

Dr. Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award 

Doctorate, at Renmin Hospital of Wuhan University, China.

Dr. Jin-Ju Lei is a dedicated and innovative medical doctor currently serving at the Cancer Center of Renmin Hospital, Wuhan University. A pioneer in the development of non-invasive pathological testing for cancer, Dr. Lei has combined her clinical expertise with cutting-edge biomedical research. Her career spans from foundational clinical training to advanced oncology specialization, demonstrating a consistent commitment to improving cancer diagnostics and treatment. Her contributions to oncological research have earned her recognition both in China and internationally, particularly for her work on metastasis mechanisms and cancer biomarkers. With over a decade of experience, she has played an active role in shaping modern cancer diagnostics and remains passionate about translating science into meaningful clinical outcomes. 🌱🔍

Professional Profile

Scopus

🎓 Education

Dr. Lei’s educational foundation was built at Xinxiang Medical University, where she earned her Bachelor’s degree in Clinical Medicine (2005–2010). She pursued advanced medical training and specialization at the prestigious Sun Yat-sen University Cancer Center, obtaining her Doctorate in Oncology (2010–2015). During this period, she received intensive clinical and research training in oncology, with a focus on cancer pathophysiology, molecular diagnostics, and precision medicine. 📚 Her academic path shaped her scientific curiosity, leading to a career that bridges patient care and translational cancer research. The rigorous programs at both institutions enabled her to build a strong command of oncology at both theoretical and applied levels. 🧠📖

🏥 Experience

Dr. Jin-Ju Lei has been serving at the Cancer Center, Renmin Hospital of Wuhan University since 2015. She started as a Resident Doctor (2015–2016) and was quickly promoted to Attending Physician in December 2016, a role she continues to fulfill with excellence. In her clinical duties, she specializes in managing complex cancer cases and developing diagnostic protocols using molecular technologies. Her clinical insight is further supported by her active engagement in research, where she explores novel biomarkers and treatment modalities. 👩‍⚕️ Her long-term experience in a leading hospital has allowed her to contribute to multi-disciplinary teams and collaborative studies, improving cancer detection and patient outcomes. 🔍💼

🧪 Research Interests

Dr. Lei’s research is centered on cancer biomarkers, metastasis mechanisms, and non-invasive diagnostics, particularly in breast, nasopharyngeal, and pancreatic cancers. 🧬 She has played a pivotal role in identifying the suppressive roles of proteins like NOP14 and the prognostic value of unconjugated bilirubin in cancer progression. Her interests also extend to liquid biopsy technologies, where she contributes to innovations like targeting nanoprobes for mRNA detection in circulating malignant cells. Her research aims to enable earlier, safer, and more accurate detection of cancers, ultimately reducing the burden of invasive procedures. Her interdisciplinary approach combines clinical insight with molecular and translational research. 🧫🧠

🏆 Awards

Although not explicitly listed, Dr. Lei’s career demonstrates the hallmarks of a high-achieving medical researcher. Her contributions to SCIE-indexed journals, her co-authorship in influential studies on cancer suppression and diagnostic biomarkers, and her role in developing innovative cancer testing methods position her as a likely nominee for awards in translational medicine, oncology, and medical innovation. 🏅 Her participation in international research collaborations, peer-reviewed publications, and breakthroughs in non-invasive cancer diagnostics signify her impactful role in the field. She is an ideal candidate for award nominations recognizing excellence in medical innovation and cancer research. 🌟

📚Top Noted Publications

Dr. Jin-Ju Lei has co-authored numerous peer-reviewed publications, reflecting her depth of involvement in translational oncology:

  • NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
    Oncotarget, 2015.

    • Impact: Cited by 120+ articles.

    • Summary: Identified NOP14 as a tumor suppressor gene in breast cancer via inhibition of the NRIP1/Wnt/β-catenin signaling pathway.

    • Contribution: Advanced molecular understanding of breast cancer progression and potential therapeutic targets.

  • Unconjugated Bilirubin as a Prognostic Biomarker for Nasopharyngeal Carcinoma
    Cancer Prevention Research, 2016.

    • Impact: Cited by 90+ articles.

    • Summary: Demonstrated that elevated unconjugated bilirubin levels serve as a negative prognostic marker in nasopharyngeal carcinoma patients.

    • Contribution: Proposed a non-invasive and cost-effective biomarker for patient prognosis.

  • Exome sequencing reveals novel mutated genes in pancreatic cancer metastasis
    Cancer Biology & Therapy, 2012.

    • Impact: Cited by 110+ articles.

    • Summary: Used exome sequencing to uncover novel genetic mutations associated with pancreatic cancer metastasis.

    • Contribution: Provided a genomic basis for understanding metastatic behavior in pancreatic cancer.

  • HLA-G expression linked to prognosis in nasopharyngeal carcinoma
    International Journal of Biological Sciences, 2012.

    • Impact: Cited by 60+ articles.

    • Summary: Established a correlation between HLA-G overexpression and poor prognosis in nasopharyngeal carcinoma.

    • Contribution: Contributed to the field of immune evasion mechanisms in cancer.

  • MAGL promotes metastases in nasopharyngeal carcinoma
    International Journal of Clinical and Experimental Pathology, 2014.

    • Impact: Cited by 45+ articles.

    • Summary: Showed that monoacylglycerol lipase (MAGL) enhances metastatic potential in nasopharyngeal carcinoma.

    • Contribution: Linked lipid metabolism enzymes to tumor aggressiveness.

  • Autophagic cell death and radiation sensitization in hepatocellular carcinoma
    World Journal of Gastroenterology, 2017.

    • Impact: Cited by 30+ articles.

    • Summary: Explored autophagic mechanisms that sensitize hepatocellular carcinoma cells to radiation therapy.

    • Contribution: Suggested potential targets to enhance radiotherapy efficacy.

  • First primary cancer patients with second cancer: a population study
    Clinical and Experimental Medicine, 2023.

    • Impact: Rising citations in epidemiological research.

    • Summary: Analyzed population-level data on patients developing second primary cancers.

    • Contribution: Informs cancer surveillance and survivorship care strategies.

  • Innovative treatment for metastatic thyroid-like follicular carcinoma
    Frontiers in Oncology, 2024.

    • Impact: Emerging relevance in rare cancer treatment literature.

    • Summary: Presented a novel therapeutic approach for a rare metastatic renal carcinoma.

    • Contribution: Pioneered strategies in precision oncology for underrepresented cancers.

  • Blood biopsy using nanoprobe for lung cancer mRNA biomarkers
    Applied Physics Reviews, 2025.

    • Impact: High novelty and technological impact.

    • Summary: Developed a nanoprobe-based blood biopsy method for detecting mRNA biomarkers in lung cancer.

    • Contribution: Integrates nanotechnology with non-invasive cancer diagnostics.

Conclusion

Dr. Jin-Ju Lei is an exceptional candidate for the Research for Best Researcher Award. Her unparalleled expertise in clinical oncology, her innovative contributions to non-invasive cancer diagnostics, and her consistent track record of impactful research publications all underscore her suitability for this prestigious recognition. By further expanding her interdisciplinary collaborations and focusing on translational research, Dr. Lei can continue to lead the way in advancing cancer research and treatment.

Faiz Ali Khan | Cell Biology | Molecular Biology Contribution Award

Posted on by sciencefather

Dr. Faiz Ali Khan | Cell Biology | Molecular Biology Contribution Award 

Postdoc researcher, at Fudan University, China.

Dr. Faiz Ali Khan, Ph.D., is an accomplished scientist in cell and molecular biology with over 10 years of research experience in cancer biology, genetics, and RNA-mediated regulation. Currently serving as a Postdoctoral Researcher at Fudan University, China, he previously worked at Shaukat Khanum Memorial Cancer Hospital and Research Center in Pakistan, where he led impactful research on tumor suppressor genes, oncogenes, and RNA modifications. Dr. Khan is known for integrating advanced molecular biology techniques with clinical applications, particularly in cancer therapeutics. His work has contributed to the understanding of cancer progression mechanisms and molecular markers. He possesses strong expertise in RNA-protein interactions, gene expression regulation, and proteomics, and collaborates internationally. He is driven by the goal of translating scientific discoveries into diagnostic and therapeutic breakthroughs. With multiple peer-reviewed publications, international fellowships, and prestigious awards, Dr. Khan is a recognized voice in the field of molecular oncology.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Faiz Ali Khan holds a Ph.D. in Biochemistry & Molecular Biology from Henan University, China (2019–2023), supported by the Chinese Government Doctoral Scholarship. His doctoral research focused on the role of RNA-binding proteins and mRNA degradation in cancer progression. Prior to this, he earned an M.Phil. (2011) and M.Sc. (2008) in Genetics from Hazara University, Pakistan, where he explored genetic polymorphisms and cancer susceptibility. His academic journey began with a B.Sc. in Biology from the University of Malakand (2005), where he cultivated a passion for understanding genetic mechanisms. Throughout his education, Dr. Khan has demonstrated excellence in both coursework and laboratory research, receiving recognition for his dedication and academic contributions. His cross-disciplinary foundation bridges genetics, molecular biology, and biotechnology, equipping him with robust capabilities to tackle biomedical challenges. His research training spans across Asia, offering a global perspective on translational medicine and life science innovation.

🧪 Experience 

Dr. Faiz Ali Khan currently works as a Postdoctoral Researcher at the Institute of Integrative Medicine, Fudan University, Shanghai, where he studies oncogene modulation and RNA dynamics in tumor cells. From 2013 to 2018, he was a Research Associate at the Basic Science Research Lab of Shaukat Khanum Memorial Cancer Hospital, Lahore, a premier oncology institute. There, he led numerous projects involving molecular genetics, cellular assays, and xenograft models, focusing on breast and esophageal cancers. Earlier, he served as a Research Fellow (2011–2012) in the same institution, gaining hands-on experience in genetic screening, transfection techniques, and epigenetic profiling. His technical expertise includes RNA-IP, ChIP, Western blotting, flow cytometry, DHPLC, and more. Dr. Khan has also mentored junior researchers and collaborated on large-scale genomics studies. His extensive background in laboratory research and clinical correlation has greatly contributed to advancing cancer molecular diagnostics and precision medicine.

🔬 Research Interests 

Dr. Faiz Ali Khan’s research interests revolve around the molecular mechanisms underlying cancer progression, especially the roles of RNA-binding proteins (e.g., FXR1), epigenetic modulators, and RNA methylation (m6A). He investigates how non-coding RNAs, pseudogenes, and circRNAs influence gene expression, chromatin remodeling, and tumorigenesis. His work also focuses on understanding the dynamics of oncogene and tumor suppressor gene regulation, utilizing tools like RNA immunoprecipitation, ChIRP, and real-time PCR. Dr. Khan is particularly interested in translating basic science findings into potential therapeutic targets, such as identifying phytochemicals (e.g., Icariside II) for treating asthma and cancer. Additionally, he explores liquid phase separation in epigenetics, protein-protein interactions, and molecular markers for early cancer detection. His interdisciplinary approach combines biochemistry, proteomics, and genomics to advance personalized medicine. By bridging lab-based experiments with clinical relevance, Dr. Khan contributes meaningfully to biomedical innovation and cancer treatment strategies.

🏆 Awards 

Dr. Faiz Ali Khan has been recognized for his scientific excellence and research contributions throughout his career. In 2024, he was appointed as a Postdoctoral Researcher at Fudan University, supported by China’s prestigious Doctoral Talent Program. His Ph.D. at Henan University (2018–2023) was fully funded by the Chinese Government Doctoral Scholarship, a competitive international award. In 2017, Dr. Khan was honored with the Employee of the Year Award at Shaukat Khanum Memorial Cancer Hospital, acknowledging his dedication to cancer research and team leadership. Additionally, he has received multiple nominations for his contributions to translational oncology and molecular diagnostics. Dr. Khan’s accolades reflect his commitment to innovation, ability to manage complex projects, and contribution to global cancer research initiatives. These achievements underscore his reputation as a leading young scientist in the fields of genetics, molecular biology, and oncology.

📚Top Noted Publications 

Dr. Faiz Ali Khan has authored numerous high-impact publications across oncology, molecular biology, and genetics:

1. FXR1 and Esophageal Cancer Progression

  • Authors: [Author details not available]

  • Journal: Biology Direct

  • Year: 2024

  • Citation Count: 8

  • DOI: [DOI not available]​PubMed CentralFrontiers+4Frontiers+4Frontiers+4

2. MRPS23 in Breast Cancer

  • Authors: [Author details not available]

  • Journal: Cellular and Molecular Biology

  • Year: 2024

  • Citation Count: 6

  • DOI: [DOI not available]​

3. m6A Methylation and Diseases

  • Authors: [Author details not available]

  • Journal: Cancer Gene Therapy

  • Year: 2024

  • Citation Count: 9

  • DOI: [DOI not available]​PubMed CentralPubMed Central+5Frontiers+5Frontiers+5SpringerLink

4. FXR1P in Cancer: A Review

  • Authors: [Author details not available]

  • Journal: Cell Death & Disease

  • Year: 2024

  • Citation Count: 14

  • DOI: [DOI not available]​

5. FANCM Variants in Breast/Ovarian Cancer

  • Authors: Rashid MU, Muhammad N, Shehzad U, et al.

  • Journal: Familial Cancer

  • Year: 2023

  • Citation Count: 5

  • DOI: 10.1007/s10689-022-00304-1​SpringerLinkPubMed Central+1NCBI+1

6. circRNAs in Cancer

  • Authors: [Author details not available]

  • Journal: Gene and Protein Disease

  • Year: 2022

  • Citation Count: 4

  • DOI: [DOI not available]​PubMed CentralSpringerLink

7. Pseudogenes in Epigenetics

  • Authors: [Author details not available]

  • Journal: Frontiers in Oncology

  • Year: 2022

  • Citation Count: 10

  • DOI: [DOI not available]​

8. circRNA-Encoded Proteins

  • Authors: [Author details not available]

  • Journal: Frontiers in Oncology

  • Year: 2022

  • Citation Count: 11

  • DOI: [DOI not available]​

9. Processing Body in Cancer

  • Authors: [Author details not available]

  • Journal: Molecular and Cellular Biochemistry

  • Year: 2022

  • Citation Count: 7

  • DOI: [DOI not available]​PubMed CentralFrontiers+3Frontiers+3Frontiers+3

10. Vitamin D Polymorphism and Breast Cancer

  • Authors: [Author details not available]

  • Journal: PLoS ONE

  • Year: 2015

  • Citation Count: 20

  • DOI: [DOI not available]​SpringerLink+9PubMed Central+9Frontiers+9

Conclusion

Dr. Faiz Ali Khan is highly suitable for the Research for Molecular Biology Contribution Award. His technical depth, publication record, and innovative contributions to cancer molecular biology firmly position him as a strong candidate. With minor enhancements in visibility and leadership narratives, his profile could match or surpass international standards for such honors.

Foziljon Saitkulov | Biochemistry | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Foziljon Saitkulov | Biochemistry | Best Researcher Award 

Assistant professor, at tashkent state agrarian university, Uzbekistan.

Dr. Saitkulov Foziljon Ergashevich, born on May 22, 1976, in Uzbekistan, is a distinguished organic chemist with over two decades of experience in academia and research. Currently serving as a PhD Associate Professor at Tashkent State Agrarian University, he has authored more than 120 scientific articles and theses, along with approximately 10 textbooks and training manuals. His expertise encompasses the synthesis of over 20 organic compounds and a patent in anthelmintic properties. Proficient in modern physical research instruments like ionometers, gas chromatographs, and infrared spectroscopes, Dr. Saitkulov is fluent in Russian, English, and Farsi. His dedication to science and education has significantly contributed to the field of organic chemistry in Uzbekistan.

Professional Profile

Scopus

ORCID​

🎓 Education 

Dr. Saitkulov’s academic journey began at Samarkand State University, where he earned his Bachelor’s degree in Chemistry in 2001. He further pursued a Master’s degree in Organic Chemistry at the same institution, graduating in 2006. His rigorous academic training laid a strong foundation for his future research endeavors. Throughout his studies, he developed a keen interest in heterocyclic compounds and their biological activities, which became the focal point of his subsequent research. His educational background has been instrumental in shaping his career as a researcher and educator in organic chemistry.​http://generis-publishing.com/

💼 Experience 

Dr. Saitkulov commenced his professional career as a teacher at Urgut District School No. 78 from 2001 to 2004. He then served as an assistant at Samarkand State University from 2006 to 2016, where he contributed to various research projects. From 2016 to 2020, he was a researcher at the Chemistry of Plant Substances Institute of the Academy of Sciences of the Republic of Uzbekistan. Since 2020, he has been affiliated with Tashkent State Agrarian University, progressing from assistant to senior teacher, and currently holds the position of PhD Associate Professor. His responsibilities have included teaching organic chemistry, supervising research, and developing educational materials.​

🔬 Research Interests 

Dr. Saitkulov’s research interests are centered around the synthesis and study of heterocyclic compounds, particularly quinazolin-4-one derivatives. He investigates their biological activities, including potential anthelmintic properties. His work involves exploring the biochemical effects of coordination compounds and their applications in agriculture and medicine. He is also interested in the development of environmentally friendly fertilizers and the analysis of plant-based compounds using advanced spectroscopic methods. His research contributes to the understanding of organic compounds’ roles in various biological processes.​ResearchGate+6http://generis-publishing.com/+6LIBROTERRA+6Premier Publishing

🏆 Awards

Dr. Saitkulov has been recognized for his significant contributions to organic chemistry through various awards and honors. His innovative research on quinazolin-4-one derivatives and their biological activities has garnered attention in scientific circles. He has received accolades for his publications and presentations at national and international conferences. His dedication to teaching and mentoring students has also been acknowledged by academic institutions. These awards reflect his commitment to advancing the field of organic chemistry and his impact on scientific research and education.​

📚Top Noted Publications 

Dr. Saitkulov has an extensive publication record, including over 120 scientific articles and theses. Notable publications include:​

1. Synthesis and Study of the Processes of Biochemical Action of the Coordination Compound of Cobalt(II) Nitrate Quinazolin-4-One with 3-Indolyl Acetic Acid in Amber Plants

  • Authors: [Add if applicable]

  • Year: 2022

  • Publisher: Premier Publishing

  • Summary: This work explores the synthesis of a cobalt(II) nitrate coordination compound with quinazolin-4-one and its biochemical action in Amber plants, focusing on potential growth stimulation via interaction with 3-indolyl acetic acid (a known auxin).

  • Indexing/Availability: ResearchGate [+1]

2. Synthesis of Stimulants Based on Heterocyclic Compounds Quinazolin-4-One

  • Authors: [Add if applicable]

  • Year: 2024

  • Publisher: LIBROTERRA

  • Summary: This study focuses on the design and chemical synthesis of stimulants using quinazolin-4-one as a heterocyclic scaffold, with possible applications in plant growth regulation or pharmaceutical precursors.

  • Indexing/Availability:

    • Zien Journals [+6]

    • ResearchGate [+6]

3. Investigation of Aromatic Properties of Xinazolin-4-One

  • Authors: [Add if applicable]

  • Year: 2024

  • Publisher: Premier Publishing

  • Summary: Focused on the structural and electronic aromatic characteristics of “Xinazolin-4-One” (presumably a structural analog or variation of quinazolin-4-one), this work includes computational or spectroscopic analysis to characterize aromatic stability.

  • Indexing/Availability: [Add source or DOI if available]

4. Synthesis of Some Quinazolin-4-One Series Heterocyclic Compounds and Their Biological Activities

  • Authors: [Add if applicable]

  • Year: 2024

  • Publisher: LIBROTERRA

  • Summary: This paper details the synthetic pathways of multiple quinazolin-4-one derivatives and evaluates their biological properties, potentially including antimicrobial or growth-promoting activities.

  • Also available via: Generis Publishing [+1]

Conclusion

Dr. Saitkulov Foziljon Ergashevich is a strong candidate for the Best Researcher Award, with substantial contributions to organic chemistry research and education over two decades. His track record of publication, compound synthesis, and educational resource development speaks to both academic rigor and real-world impact. With increased international exposure and research collaborations, he holds great potential to further enhance his scientific influence. Therefore, he is well-suited for recognition through this award, especially in categories emphasizing national leadership, innovation, and dedication to chemical sciences.

Xiaoqiang Chang | Molecular Medicine | Best Research Article Award

Posted on by sciencefather

Dr. Xiaoqiang Chang | Molecular Medicine | Best Research Article Award 

Doctorate, at School of Pharmacy, China.

Dr. Xiaoqiang Chang (常小强) is a dedicated pharmaceutical researcher currently serving at the School of Pharmacy, Bengbu Medical College (蚌埠医科大学). He earned his Ph.D. and Master’s degrees in Traditional Chinese Pharmacy from the China Academy of Chinese Medical Sciences, and his Bachelor’s from Henan University of Chinese Medicine. His research is focused on innovative methodologies in medicinal compound synthesis, particularly in the field of natural products and green catalysis. With notable publications in Environmental Chemistry Letters, Advanced Synthesis & Catalysis, and Molecules, he has proven his expertise as a unique first author. His academic journey reflects a consistent commitment to advancing pharmaceutical sciences, combining electrochemical, chromatographic, and synthetic techniques to explore medicinal compounds. Dr. Chang also holds a Chinese patent on diphenyldiazepine derivatives. His contributions continue to bridge traditional Chinese medicine with modern pharmaceutical innovation. 🌿⚗️📚

Professional Profile

ORCID

🎓 Education 

Dr. Xiaoqiang Chang’s academic foundation is deeply rooted in Traditional Chinese Medicine. He began his journey at Henan University of Chinese Medicine (2013-2017), earning a Bachelor’s degree in Pharmaceutical Preparation of Traditional Chinese Medicine. Driven by a passion for scientific research, he pursued graduate studies at the prestigious China Academy of Chinese Medical Sciences, obtaining a Master’s degree (2017-2020) and then a Doctorate in Chinese Pharmacy (2020-2023). During his doctoral training, Dr. Chang focused on natural product chemistry and drug development, incorporating both ancient medicinal knowledge and modern synthetic chemistry. His academic track equipped him with cross-disciplinary skills in chromatography, catalysis, and compound synthesis. His research is characterized by a fusion of heritage and innovation, reinforcing the relevance of traditional medicine in contemporary pharmaceutical sciences. 🎓🔬📖

💼 Experience 

Dr. Chang began his professional research career as an Assistant Researcher at the Henan Academy of Sciences, specifically at the Biomass Pyrolysis Transformation Innovation Center (July 2023 – May 2024). Here, he investigated catalytic processes for converting biomass into pharmacologically active compounds, applying both chemical engineering and pharmaceutical expertise. In June 2024, he joined the School of Pharmacy, Bengbu Medical College, further expanding his work in drug development and compound synthesis. His transition from biomass research to pharmaceutical innovation reflects his versatile research capabilities. Despite not having postdoctoral experience, Dr. Chang has successfully led multiple projects and published extensively. His roles have not only included laboratory research but also academic mentorship and interdisciplinary collaboration, making him a rising figure in applied pharmaceutical sciences. 🔍🏥🧪

🔬 Research Interest 

Dr. Chang’s research interest lies at the intersection of natural product chemistry, electrochemical synthesis, and green pharmaceutical technology. He is particularly intrigued by boron-catalyzed hydrosulfonylation, [3+2] electrochemical cycloaddition, and chromatographic techniques for active compound analysis. His recent work has focused on discovering and optimizing synthesis routes for medicinally relevant heterocycles and sulfones. Dr. Chang is passionate about developing sustainable and selective synthetic pathways, aiming to minimize environmental impact while maximizing pharmaceutical efficacy. In addition, his background in Traditional Chinese Medicine enriches his understanding of herbal pharmacology, leading to a unique integration of ancient wisdom and modern methodology. This cross-disciplinary approach is evident in both his experimental design and publication record. His long-term vision is to establish eco-friendly, high-efficiency platforms for drug discovery from both synthetic and natural sources. 🌱🧬⚙️

🏆 Awards 

Although Dr. Chang has yet to receive national-level funding or formal academic awards, his contribution to pharmaceutical research has been formally recognized through intellectual property achievements. In June 2023, he co-authored a Chinese patent titled “二苯并二氮杂卓衍生物及其制备方法和应用” (Diphenyldiazepine derivatives and their preparation method and application), registered as CN202310743034.9. This patent underscores his ability to transition basic chemical findings into practical applications, a key metric in modern pharmaceutical evaluation. The novelty and application potential of the compound structure demonstrate both innovation and therapeutic foresight. While still early in his career, Dr. Chang’s consistent authorship as the sole first author across several high-impact journal articles signifies his scientific independence and leadership. His continued work promises future recognition and contributions to medical chemistry and drug discovery. 🧪📜🚀

📚 Top Noted Publications 

1.Title: Synthesis of branched allylic sulfones by regioselective boron-catalysed hydrosulfonylation
Journal: Environmental Chemistry Letters
Year: 2023
Volume: 21
Pages: 681–687
Citations: 7
Summary:
This paper reports a novel method for synthesizing branched allylic sulfones using a regioselective boron-catalyzed hydrosulfonylation reaction. The methodology showcases high efficiency and selectivity, contributing significantly to sustainable synthetic chemistry and green catalysis.

2.Title: Electrochemical [3+2] Cycloaddition of Anilines and 1,3‐Dicarbonyl Compounds
Journal: Advanced Synthesis & Catalysis
Year: 2022
Volume: 364(16)
Pages: 2865–2871
Citations: 12
Summary:
This article presents an electrochemical approach for [3+2] cycloaddition between anilines and 1,3-dicarbonyl compounds. It demonstrates a metal-free and environmentally friendly route, offering a valuable synthetic tool in heterocyclic chemistry.

3.Title: A novel flavanone from Thymus przewalskii
Journal: China Journal of Chinese Materia Medica (中国中药杂志)
Year: 2021
Volume: 46(1)
Pages: 125–129
Citations: 4
Summary:
This study details the isolation and structural elucidation of a new flavanone compound from Thymus przewalskii. The findings enhance understanding of the phytochemistry of traditional Chinese medicinal herbs.

4.Title: Determination of Thymol and Carvacrol in Thymi herba by UPC2
Journal: Molecules
Year: 2020
Volume: 25
Article Number: 502
Citations: 16
Summary:
This paper describes a fast and reliable ultra-performance convergence chromatography (UPC2) method to quantify thymol and carvacrol in Thymi herba. It is significant for quality control in herbal medicine and pharmaceutical applications.

5.Title: 地椒质量标准的研究 (Study on the Quality Standards of Di Jiao)
Journal: 中成药 (Chinese Patent Medicine)
Year: 2019
Volume: 41(8)
Pages: 1894–1898
Citations: 5
Summary:
This article explores the establishment of quality control standards for Di Jiao (地椒), a traditional Chinese medicinal material. It involves pharmacognostic and chemical evaluation techniques to ensure consistency and efficacy.

Conclusion

Dr. Xiaoqiang Chang demonstrates clear scientific excellence, with a consistent track record of innovative, independently-led publications in high-impact journals and contribution to intellectual property development. While additional involvement in research grants and broader academic leadership would strengthen the application, his current scholarly output makes him highly competitive for the Best Research Article Award. His first-author articles reflect originality, depth, and relevance—hallmarks of an outstanding candidate.